Rexahn Pharmaceuticals, Inc. (NYSE: RNN) is a clinical-stage biopharmaceutical company dedicated to the development of novel, best-in-class therapeutics for the treatment of cancer. The company’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Rexahn’s development pipeline includes three anti-cancer compounds currently in clinical development – including Supinoxin™, RX-3117 andArchexin® – as well as a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information, visit the company’s website at www.rexahn.com.